The announcement comes a day after the Subject Expert Committee (SEC) on COVID-19 of the CDSCO recommended granting emergency use authorisation (EUA) to the COVID-19 vaccines Covovax and Corbevax with certain conditions.
As many as 24 special economic zone (SEZ) developers including Dr Reddy's Lab and Tata Consultancy Services have sought more time from the government to execute their projects.
Sun Pharma stock has appreciated at 35% a year for 20 years
The Serum Institute of India, Bharat Biotech and Pfizer have applied to the DCGI seeking emergency use authorisation for their COVID-19 vaccine candidates and are awaiting approval.
A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
The modalities of COVID-19 vaccine delivery, distribution and administration were discussed during the meeting.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
Tata Steel was the top loser in the Sensex pack, sinking over 5 per cent, followed by SBI, IndusInd Bank, Bajaj Finance, HDFC Bank and NTPC. NSE Nifty tanked 371 points to 16,614.20.
The official expressed hope on the success of the five vaccines that are under different phases of trial in the country.
Drugmaker Dr Reddy's Laboratories has filed an application with the US Food and Drug Administration to market a generic form of Eli Lilly's schizophrenia drug Olanzapine in the US
They seek to profit from big-selling drugs going off-patent this year in the lucrative market.
"Sputnik will probably offer vaccines after June 20. They will start the vaccine production from the month of August. They are importing the vaccines right now, and they will allot a section of their imported vaccines to the Delhi government," he said.
Rosier year-end seen for Indian pharma thanks to faster US approvals.
The 50-share NSE index Nifty rose by 24.95 points, or 0.41 per cent, to settle at 6,073.30.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
Polarisation and the increase in index weight of a few a stocks have weighed on performance. The worst performers include Nippon India Large Cap and HDFC Top 100 (2.6 per cent).
It said clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
Many say trend could lead to concerns on manufacturing quality in Indian facilities.
National Pharmaceutical Pricing Authority names Cipla, Dr Reddy's Labs and Ranbaxy among those.
Indices reversed all its losses during late trades.
Nifty PSU Bank index gained 1% led by Allahabad Bank, Andhra Bank, Syndicate Bank and IDBI Bank
'In his demise, the world of Telugu language and literature has lost a bright star. The void caused by his loss can never be filled.'
The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.
Dr Reddy, an innovative technocrat par excellence, led from the front the countless initiatives of his famed laboratory in discovering many effective, affordable, cures for the numerous ailments of mankind, writes Shreekant Sambrani.
Such businesses outperform non-family firms by 3% in first six months of CY20, says Credit Suisse report.
Disappointed with past experience, domestic majors even skip giving any memorandum.
Participants will watch out for the Brexit poll outcome in the late morning trades tomorrow.
Yusuf Hamied, Anji Reddy and Parvinder Singh are the real pioneers of the Indian pharmaceutical industry.
Fabiflu sales have grown by 62 per cent in July. It was launched in June. This drug is being used by doctors for mild-to-moderate Covid patients even if they are in home isolation.
Companies say they follow global standards in India as well
Regulator says fee would enable it to quicken approval process.
